Ionis, Roche Set New Pact Targeting Alzheimer's, Huntington's
27 Setembro 2023 - 8:59AM
Dow Jones News
By Colin Kellaher
Ionis Pharmaceuticals is teaming up with longtime partner Roche
Holdings on a pair of early stage programs for RNA-targeting
investigational medicines for the treatment of the brain disorders
Alzheimer's disease and Huntington's disease.
Ionis on Wednesday said it will have responsibility to advance
the two programs through pre-clinical studies, while Roche will
have sole responsibility for clinical development and
commercialization worldwide.
Ionis said it will receive a $60 million upfront payment from
Roche, adding that it is eligible for development, regulatory and
commercial milestone payments, along with royalties.
Carlsbad, Calif.-based Ionis and Swiss drug giant Roche have
been working together since 2013 and have candidates in clinical
studies targeting Huntington's, IgA nephropathy and geographic
atrophy.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 27, 2023 07:44 ET (11:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Ionis Pharmaceuticals (NASDAQ:IONS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024